Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Net Income (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Net Income data on record, last reported at -$203.6 million in Q4 2025.

  • For Q4 2025, Net Income fell 460.37% year-over-year to -$203.6 million; the TTM value through Dec 2025 reached -$122.2 million, up 38.23%, while the annual FY2025 figure was -$122.2 million, 38.23% up from the prior year.
  • Net Income reached -$203.6 million in Q4 2025 per APLS's latest filing, down from $215.7 million in the prior quarter.
  • Across five years, Net Income topped out at $402.7 million in Q4 2022 and bottomed at -$219.2 million in Q2 2021.
  • Average Net Income over 5 years is -$59.9 million, with a median of -$107.1 million recorded in 2023.
  • The widest YoY moves for Net Income: up 475.52% in 2025, down 460.37% in 2025.
  • A 5-year view of Net Income shows it stood at $283.4 million in 2021, then surged by 42.1% to $402.7 million in 2022, then crashed by 109.95% to -$40.1 million in 2023, then grew by 9.36% to -$36.3 million in 2024, then crashed by 460.37% to -$203.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$203.6 million in Q4 2025, $215.7 million in Q3 2025, and -$42.2 million in Q2 2025.